PuraCath FireflyTM Can Kill Deadly Microorganisms with UV Light, Like SARS CoV-2

President Trump has officially declared a national emergency. A novel coronavirus has been identified in Wuhan City, China and has spread worldwide. It has been named SARS CoV-2 (causing disease COVID-19) by WHO. SARS CoV-2 has officially become a global pandemic by WHO. There have already been over 170,000 confirmed cases to date with an average of a 3% death rate. Every U.S. state, other than West Virginia, has confirmed cases of COVID-19. This link ¹ has the most up to date information on total COVID-19 confirmed cases and deaths. One of the dangers is that the onset of symptoms can occur up to 14 days after exposure, which may vary with age and other underlying health conditions. The Center for Disease Control (CDC) says that one can acquire COVID-19 by being 6 feet away from an infected person if they do not have personal protective equipment.

PuraCath’s Firefly ^TM disinfection technology has been successfully tested on other resistant and deadly microorganisms like Methicillin Resistant Staphyloccus Aureus (MRSA) and Candida Auris and proven to reduce 99.99% of those microorganisms with only 1 second of Firefly ^TM UV light. Moreover, in a study published by Cheng et al ² , UV germicidal irradiation (UVGI) was shown to effectively inactivate encapsulated coronavirus (like SARS, MERS, SARS CoV-2) and H5N1 virus. The wavelengths of UV-C that prove germicidal effect are between 185 nm to 285 nm and the same to the wavelengths used in the Firefly ^TM disinfection technology. As such, PuraCath’s standard protocols should be sufficient to eliminate 99.99% of SARS CoV-2.

The PuraCath Firefly device can help utilize UV light to protect nurse-to-patient or patient-to-patient transmission of the SARS CoV-2 in patients with Midlines, PICC, CVC, or IV lines ($3.6B+ US market). These patients can be at home or in hospitals and typically in the ICU. Moreover, these are typically immunocompromised or immunosuppressed patients who are most susceptible to acquire SARS CoV-2 and experience higher fatality rates.

Besides the Firefly ^TM , PuraCath is also working on expanding its platform to other devices to help patients and consumers protect themselves from viruses like the SARS CoV-2.